Demand continues to rise, and those who hesitate risk losing access
In discussions around GLP 1 therapies, Huberman consistently points out that while pharmacology can drive significant fat loss, long term outcomes still depend on training, nutrition, and lifestyle structure
Biggest shake-up in type 2 diabetes care in a decade announced
Tesamorelin A growth hormone-releasing hormone (GHRH) analog that specifically targets visceral adipose tissue the dangerous belly fat linked to metabolic disease, cardiovascular risk, and systemic inflammation
Incidence of hypoglycaemia with tirzepatide was similar vs placebo and lower vs basal insulin
What Would Change the Timeline scenarios , not forecasts